Dow Jones

42 635,20

0,25%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

HUMA

Humacyte (HUMA)

Humacyte Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:HUMA

1 2 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
06/01/2025	11h45	PR Newswire (US)	Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - HUMA	NASDAQ:HUMA	Humacyte Inc
02/01/2025	17h40	PR Newswire (US)	The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders	NASDAQ:HUMA	Humacyte Inc
02/01/2025	16h07	PR Newswire (US)	Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA	NASDAQ:HUMA	Humacyte Inc
30/12/2024	11h45	PR Newswire (US)	The Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA	NASDAQ:HUMA	Humacyte Inc
26/12/2024	11h45	PR Newswire (US)	Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA	NASDAQ:HUMA	Humacyte Inc
23/12/2024	11h45	PR Newswire (US)	Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA	NASDAQ:HUMA	Humacyte Inc
12/12/2024	11h45	PR Newswire (US)	Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact The Gross Law Firm	NASDAQ:HUMA	Humacyte Inc
05/12/2024	11h45	PR Newswire (US)	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit - HUMA	NASDAQ:HUMA	Humacyte Inc
03/09/2024	22h23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HUMA	Humacyte Inc
03/09/2024	22h11	Edgar (US Regulatory)	Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NASDAQ:HUMA	Humacyte Inc
29/08/2024	22h31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:HUMA	Humacyte Inc
13/08/2024	22h47	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HUMA	Humacyte Inc
13/08/2024	13h04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HUMA	Humacyte Inc
08/03/2024	22h03	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:HUMA	Humacyte Inc
29/02/2024	22h11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:HUMA	Humacyte Inc
12/09/2023	02h03	Dow Jones News	Stocks to Watch: Oracle, Acelyrin, Humacyte	NASDAQ:HUMA	Humacyte Inc
31/07/2023	19h28	Dow Jones News	Humacyte Shares Rise 8% After Completing Enrollment in Phase 2/3 Trial	NASDAQ:HUMA	Humacyte Inc
16/06/2023	22h14	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:HUMA	Humacyte Inc
15/06/2023	22h25	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:HUMA	Humacyte Inc
09/06/2023	22h05	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:HUMA	Humacyte Inc
08/06/2023	22h07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:HUMA	Humacyte Inc
24/05/2023	22h53	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NASDAQ:HUMA	Humacyte Inc
12/05/2023	22h20	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:HUMA	Humacyte Inc
28/04/2023	12h45	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:HUMA	Humacyte Inc
24/03/2023	13h51	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:HUMA	Humacyte Inc
10/11/2022	16h30	TipRanks	Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Humacyte (HUMA)	NASDAQ:HUMA	Humacyte Inc
19/09/2022	22h42	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:HUMA	Humacyte Inc
15/09/2022	12h33	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:HUMA	Humacyte Inc
12/09/2022	12h31	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:HUMA	Humacyte Inc
09/09/2022	22h44	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:HUMA	Humacyte Inc